Evidence map›Paper›PMID 31260455›Full record

Observational studyPloS one2019

A prospective study of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected children from high prevalence countries.

Mark F Cotton, Helena Rabie, Elisa Nemes, Hilda Mujuru, Raziya Bobat, Boniface Njau, Avy Violari, Vidya Mave, Charles Mitchell, James Oleske and 4 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Tuberculous Meningitis Across the Lifespan.The Journal of infectious diseases · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 5 countries.

Mark F CottonDepartment of Pediatrics & Child Health, Stellenbosch University, Tygerberg, South Africa.ORCID 0000-0003-2559-6034
Helena RabieDepartment of Pediatrics & Child Health, Stellenbosch University, Tygerberg, South Africa.
Elisa NemesSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Pathology, University of Cape Town, Cape Town, South Africa.
Hilda MujuruDepartment of Pediatrics, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Raziya BobatDepartment of Pediatrics & Child Health, University of KwaZulu-Natal, Durban, South Africa.
Boniface NjauKilimanjaro Christian Medical Centre, Moshi, Tanzania.
Avy ViolariDepartment of Pediatrics & Child Health, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Vidya MaveBJ Medical College, Pune, India.
Charles MitchellDepartment of Pediatric Immunology, University of Miami, Miami, FL, United States of America.
James OleskeDepartment of Pediatrics & Child Health, Rutgers New Jersey Medical School, Newark, NJ, United States of America.
Bonnie ZimmerFrontier Science & Technology Research Foundation, Amherst, NY, United States of America.
George VargheseDepartment of Pediatrics & Child Health, University of Miami Miller School of Medicine, Miami, FL, United States of America.
Savita PahwaDepartment of Pediatrics & Child Health, University of Miami Miller School of Medicine, Miami, FL, United States of America.
P1073 team
University of Miami · USStellenbosch University · ZAB. J. Medical College & Sassoon Hospital · INFrontier Science & Technology Research Foundation · USKilimanjaro Christian Medical Centre · TZRutgers, The State University of New Jersey · USUniversity of Cape Town · ZAUniversity of KwaZulu-Natal · ZAUniversity of the Witwatersrand · ZAUniversity of Zimbabwe · ZW

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Soweto Clinical Trials UnitUM1AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI Glenda E Gray, Lerato Mohapi · 2012 to 2026
$40.9M
Stellenbosch University Clinical Trial Unit, Cape Town, South AfricaUM1AI069521 · NIAID · STELLENBOSCH UNIVERSITY · PI Shaun Barnabas, Anneke Catharina Hesseling · 2012 to 2026
$21.5M
Stellenbosch University Clinical Trial Unit, Cape Town, South AfricaU01AI069521 · NIAID · STELLENBOSCH UNIVERSITY · PI COTTON, MARK FREDRIC · 2007 to 2011
$8.4M
NIAID NIH HHS U01 AI069436NIAID NIH HHS U01 AI069521NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069453NIAID NIH HHS UM1 AI069521NIAID NIH HHS UM1 AI106716NICHD NIH HHS HHSN275201800001CNICHD NIH HHS HHSN275201800001I
6 · The paper itself

Abstract

backgroundThe immune reconstitution inflammatory syndrome (IRIS) in HIV-infected infants and young children is relatively understudied in regions endemic for HIV and TB. We aimed to describe incidence, clinical features and risk factors of pediatric IRIS in Sub-Saharan Africa and India. METHODS AND

findingsWe conducted an observational multi-centred prospective clinical study from December 2010 to September 2013 in children <72 months of age recruited from public antiretroviral programs. The main diagnostic criterion for IRIS was a new or worsening inflammatory event after initiating antiretroviral therapy (ART). Among 198 participants, median age 1.15 (0.48; 2.21) years, 38 children (18.8%) developed 45 episodes of IRIS. Five participants (13.2%) had two IRIS events and one (2.6%) had 3 events. Main causes of IRIS were BCG (n = 21; 46.7%), tuberculosis (n = 10; 22.2%) and dermatological, (n = 8, 17.8%). Four TB IRIS cases had severe morbidity including 1 fatality. Cytomegalovirus colitis and cryptococcal meningitis IRIS were also severe. BCG IRIS resolved without pharmacological intervention. On multivariate logistic regression, the most important baseline associations with IRIS were high HIV viral load (likelihood ratio [LR] 10.629; p = 0.0011), recruitment at 1 site (Stellenbosch University) (LR 4.01; p = 0.0452) and CD4 depletion (LR 3.4; p = 0.0654). Significantly more non-IRIS infectious and inflammatory events between days 4 and 17 of ART initiation were noted in cases versus controls (35% versus 15.2%: p = 0.0007).

conclusionsIRIS occurs commonly in HIV-infected children initiating ART and occasionally has severe morbidity. The incidence may be underestimated. Predictive, diagnostic and prognostic biomarkers are needed.

Indexed as

ColitisCytomegalovirus InfectionsHIV InfectionsImmune Reconstitution Inflammatory SyndromeMeningitis, CryptococcalAfrica South of the SaharaChild, PreschoolCryptococcusCytomegalovirusFemaleHIV-1HumansIncidenceIndiaInfantMale

Identifiers

PMID31260455
PMCPMC6602181
OpenAlexW2955726365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.